Indomethacin tocolysis and neurodevelopmental outcome

Area of Science:

• Neonatalogy
• Developmental Pediatrics
• Pharmacology

Background:

• Antenatal indomethacin is used to manage preterm labor and other conditions.
• Its impact on long-term neurodevelopmental outcomes in extremely preterm infants requires careful evaluation.

Purpose of the Study:

• To compare neurodevelopmental outcomes at 30-42 months corrected age.
• To assess infants exposed to antenatal indomethacin versus those not exposed.

Main Methods:

• Retrospective cohort study of nonanomalous infants born between 2000-2003.
• Included infants with birth weight ≤1250g and/or gestational age ≤28 weeks.
• Neurodevelopmental assessments performed at 30-42 months corrected age.

Main Results:

• Infants exposed to antenatal indomethacin had lower gestational age and increased incidence of patent ductus arteriosus (PDA) and bronchopulmonary dysplasia.
• No significant differences were observed in cerebral palsy, cognitive delay, deafness, blindness, or major disability.
• Multivariable analysis showed no association between antenatal indomethacin and cerebral palsy, cognitive delay, or overall neurodevelopmental disability.

Conclusions:

• Neurodevelopmental outcomes are equivalent between preterm infants exposed and unexposed to antenatal indomethacin.
• Antenatal indomethacin does not appear to adversely affect neurodevelopmental trajectories in this cohort.
• This finding supports the use of antenatal indomethacin when indicated, despite potential short-term morbidities.